Yes, marijuana is a controlled substance under federal law. It is classified as a Schedule I drug under the Controlled Substances Act, placing it in the most restrictive category alongside heroin, LSD, and ecstasy. This classification means the federal government considers marijuana to have a high potential for abuse and no currently accepted medical use, even though dozens of states have legalized it in some form.
What Schedule I Means
The Controlled Substances Act, passed in 1970, organizes drugs into five categories (schedules) based on their potential for abuse, accepted medical applications, and likelihood of causing dependence. Schedule I is the most restrictive tier. Drugs placed here are considered to have no accepted medical use in the United States and a high potential for abuse. Marijuana has remained in this category for over 50 years.
This classification has real consequences. Because Schedule I substances are considered to have no medical value under federal law, research on marijuana has historically been far more difficult to conduct than research on less restricted drugs. Scientists studying Schedule I substances face additional layers of federal approval and oversight that don’t apply to drugs in lower schedules.
How Federal Law Affects You
Under federal statute, simple possession of marijuana carries a maximum sentence of one year in prison and a minimum fine of $1,000 for a first offense. In practice, federal prosecutors rarely pursue small possession cases, but the legal authority remains on the books.
The impact goes beyond criminal penalties. Internal Revenue Code Section 280E bars businesses that traffic in Schedule I or II controlled substances from claiming standard tax deductions and credits. This means state-legal marijuana dispensaries and growers pay federal taxes on their gross income rather than their net profits, a financial burden that doesn’t apply to any other legal industry. A marijuana business earning $1 million in revenue with $700,000 in operating costs gets taxed on the full $1 million, not the $300,000 in actual profit. This single provision costs the cannabis industry hundreds of millions of dollars each year.
The State vs. Federal Conflict
The most confusing part of marijuana’s legal status is the gap between federal and state law. Most states have legalized marijuana for medical use, recreational use, or both. Yet none of that changes its federal classification. You can walk into a licensed dispensary in Colorado or California, buy marijuana legally under state law, and still technically be committing a federal crime.
In 2013, the Department of Justice issued what’s known as the Cole Memo, which directed federal prosecutors to focus their resources on specific priorities rather than going after individuals and businesses complying with state marijuana laws. Those priorities included preventing distribution to minors, stopping revenue from flowing to criminal organizations, and preventing marijuana from crossing into states where it remained illegal. The memo essentially told federal attorneys to leave state-legal operations alone as long as states maintained strong regulatory systems. This guidance was rescinded in 2018 under then-Attorney General Jeff Sessions, though federal prosecutors have largely continued the hands-off approach in practice.
Hemp vs. Marijuana: The 0.3% Line
Not all cannabis is treated as a controlled substance. The 2018 Farm Bill carved out an exception for hemp, defining it as any part of the cannabis plant containing no more than 0.3% delta-9 THC on a dry-weight basis. Anything at or below that threshold is legal under federal law and removed from the Controlled Substances Act entirely.
This distinction is why CBD products are widely sold across the country. As long as a CBD product is derived from hemp and contains less than 0.3% delta-9 THC, it doesn’t violate the Controlled Substances Act. Marijuana, by contrast, typically contains 15% to 25% THC or more, keeping it firmly within Schedule I territory. The two plants are biologically the same species; the legal difference comes down entirely to THC concentration.
The Push to Reschedule
The federal government has taken steps toward moving marijuana out of Schedule I. The DEA published a proposed rule to reschedule marijuana from Schedule I to Schedule III, which would represent the first change to its federal classification since 1970. Schedule III drugs are recognized as having accepted medical uses and a lower potential for abuse. Other Schedule III substances include certain anabolic steroids and some medications containing small amounts of codeine.
Formal administrative hearings on the rescheduling proposal began in January 2025 at the DEA’s hearing facility in Arlington, Virginia, with sessions scheduled through early March. The process involves receiving factual evidence and expert testimony on whether marijuana meets the criteria for Schedule III. Even if rescheduling is finalized, marijuana would not become legal. It would still be a controlled substance requiring a prescription for medical use, and recreational sales would still conflict with federal law. However, the shift would ease research restrictions, potentially eliminate the Section 280E tax burden on cannabis businesses, and remove the symbolic equivalence between marijuana and heroin.
FDA-Approved Cannabis Medications
Despite marijuana’s Schedule I status, the FDA has approved one cannabis-derived prescription drug: Epidiolex, a purified form of CBD used to treat severe seizure disorders in patients one year of age and older. The FDA approved it in 2018 after a standard drug review process that weighed its benefits against identified risks, including the potential for liver injury. Epidiolex is not classified as Schedule I because it went through the FDA approval pathway and demonstrated accepted medical use.
This creates an unusual situation where a purified compound from the cannabis plant is a legal prescription medication, while the plant itself remains in the most restrictive federal drug category. The FDA has not approved any other CBD or cannabis-derived products and maintains that the drug approval process is the appropriate path for establishing the safety and effectiveness of cannabis-based medicines.
International Treaty Obligations
The U.S. isn’t acting in isolation when it comes to marijuana’s controlled status. The 1961 Single Convention on Narcotic Drugs, an international treaty signed by most countries, requires member nations to limit cannabis production, trade, and use exclusively to medical and scientific purposes. Cannabis was actually placed in the convention’s most restrictive schedule, which recommended prohibiting even its medical use.
These treaty obligations complicate any effort to fully legalize marijuana at the federal level. While the U.S. could theoretically withdraw from or modify its treaty commitments, doing so would be diplomatically significant. Rescheduling marijuana to Schedule III, rather than removing it from the controlled substances list entirely, would keep the U.S. in closer alignment with its international obligations while still loosening domestic restrictions.